Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

1. Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening at 11-13 Weeks Gestation

Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening at 11-13 Weeks Gestation "Comparison of FMF and NICE Algorithms in Early Preeclampsia Screening " by Lauren Voelker and Mergitu Gemeda < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background:Approximately 3% of pregnant women develop preeclampsia at some time during their pregnancy. Preeclampsia (...) is a common cause of maternal and fetal morbidity and mortality worldwide. Currently there are 3 assessment tools for preeclampsia: the National Institute for Health and Care Excellence (NICE) guidelines, the American College of Obstetricians and Gynecologist (ACOG) and the Fetal Medicine Foundation (FMF) algorithm. Both NICE and ACOG guidelines use maternal demographics and medical history as a screening tool. The more recent approach, FMF uses Bayes theorem utilizes biophysical and biochemical markers

2019 Pacific University EBM Capstone Project

2. Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. (PubMed)

Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. preeclampsia can be associated with future renal disease.To measure changes in renal function overtime in patients with preeclampsia.urine and serum samples from eleven patients with preeclampsia and eight patients with a normal pregnancy were obtained during pregnancy, postpartum, and 3 years after delivery. Urine podocalyxin, protein, and serum creatinine were measured.after 3 (...) years, there were no significant differences in urinary podocalyxin in patients with or without preeclampsia: 4.34 ng/mg [2.69, 8.99] vs. 7.66 ng/mg [2.35, 13], p = 0.77. The same applied to urinary protein excretion: 81.5 mg/g [60.6, 105.5] vs. 43.2 mg/g [20.9, 139.3] p = 0.23. Serum creatinine was 0.86 mg/dL [0.7, 0.9] vs. 0.8 mg/dL [0.68, 1] p = 0.74 in those with and without preeclampsia. In normal patients, urinary podocalyxin decreased from 54.4 ng/mg [34.2, 76.9] during pregnancy to 7.66 ng

Full Text available with Trip Pro

2019 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain

3. Predictive performance of the competing risk model in screening for preeclampsia

Predictive performance of the competing risk model in screening for preeclampsia The established method of screening for preeclampsia is to identify risk factors from maternal demographic characteristics and medical history; in the presence of such factors the patient is classified as high risk and in their absence as low risk. However, the performance of such an approach is poor. We developed a competing risks model, which allows combination of maternal factors (age, weight, height, race (...) , parity, personal and family history of preeclampsia, chronic hypertension, diabetes mellitus, systemic lupus erythematosus or antiphospholipid syndrome, method of conception and interpregnancy interval), with biomarkers to estimate the individual patient-specific risks of preeclampsia requiring delivery before any specified gestation. The performance of this approach is by far superior to that of the risk scoring systems.The objective of the study was to examine the predictive performance

Full Text available with Trip Pro

2019 EvidenceUpdates

4. Serum magnesium as a biomarker predicting the risk of development of preeclampsia

Serum magnesium as a biomarker predicting the risk of development of preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

5. Preeclampsia resolution after fetal death in multifetal gestations: a systematic literature review

Preeclampsia resolution after fetal death in multifetal gestations: a systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

6. Hepatic rupture in preeclampsia and HELLP Syndrome: review of a catastrophic presentation

Hepatic rupture in preeclampsia and HELLP Syndrome: review of a catastrophic presentation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

7. Is aspirin effective in reducing the rate of preeclampsia when it is initiated before 11 weeks of gestation as compared to placebo?

Is aspirin effective in reducing the rate of preeclampsia when it is initiated before 11 weeks of gestation as compared to placebo? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

8. Prevalence, incidence, trends and associated factors of preeclampsia among pregnant women in sub Saharan Africa: a systematic review and meta-analysis

Prevalence, incidence, trends and associated factors of preeclampsia among pregnant women in sub Saharan Africa: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

9. Aspirin in the prevention of preeclampsia in women with pre-existing diabetes: systematic review (and meta-analysis)

Aspirin in the prevention of preeclampsia in women with pre-existing diabetes: systematic review (and meta-analysis) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

10. The relationship between NSAID use and worsening hypertension among postpartum women with preeclampsia

The relationship between NSAID use and worsening hypertension among postpartum women with preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

11. The prevention of preeclampsia with prophylactic aspirin: a systematic review

The prevention of preeclampsia with prophylactic aspirin: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

12. The best magnesium sulfate regimen in preeclampsia prevention

The best magnesium sulfate regimen in preeclampsia prevention Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

13. Doppler parameters of renal hemodynamics in women with preeclampsia: a systematic review and network meta-analysis

Doppler parameters of renal hemodynamics in women with preeclampsia: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

14. Rate of preeclampsia and fetal growth restriction in women with congenital heart disease: systematic review and meta-analysis

Rate of preeclampsia and fetal growth restriction in women with congenital heart disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

15. Maternal risk for cardiovascular disease after pregnancies complicated by preeclampsia: a systematic review and meta-analysis

Maternal risk for cardiovascular disease after pregnancies complicated by preeclampsia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

16. Markers of podocyte dysfunction in preeclampsia: a systematic review and meta-analysis

Markers of podocyte dysfunction in preeclampsia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

17. The association of gestational thyroid function and thyroid autoimmunity with gestational hypertension and preeclampsia

The association of gestational thyroid function and thyroid autoimmunity with gestational hypertension and preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

18. Studies reporting on the diagnostic accuracy of ophthalmic artery Doppler for preeclampsia

Studies reporting on the diagnostic accuracy of ophthalmic artery Doppler for preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

19. Deficiency of vitamin D during pregnancy. Preeclampsia and prematurity

Deficiency of vitamin D during pregnancy. Preeclampsia and prematurity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

20. A systematic review of the impact of social and economic determinants of health and the occurrence of preeclampsia

A systematic review of the impact of social and economic determinants of health and the occurrence of preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO